Valvular & structural heart disease
Treatment effects of dapagliflozin in patients with aortic stenosis undergoing transcatheter aortic valve implantation across left ventricular ejection fraction
Authors' conclusion
In elderly patients undergoing TAVI, dapagliflozin reduced the risk of all-cause death or worsening HF irrespective of baseline LVEF and was safe across the full LVEF spectrum.
Study context
- Population
- Elderly patients with severe AS undergoing transcatheter aortic valve implantation (TAVI), by baseline left ventricular ejection fraction (LVEF) (≤40% vs >40%)with available baseline LVEF
- Participants
- 1,223 patients
- Comparison
- Dapagliflozin vs standard of care, by baseline LVEF
- Primary endpoint
- All-cause death or worsening heart failure (HF)
- Follow-up
- 1-year follow-up
Methodological detailspragmatic, multicentre, open-label, blinded endpoint adjudication, 39 Spanish centres
- Pragmatic
- Multicentre
- Open-label
- Blinded endpoint adjudication
- 39 Spanish centres
Primary result
As reported in the abstract
All-cause death or worsening HF, treatment effect by LVEF subgroup
- No significant interaction between treatment effect and baseline LVEF
- P for interaction = .41
Further findings
| Outcome | LVEF ≤40% | LVEF >40% | Adjusted HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Primary endpoint by baseline LVEF (prognosis) · 1-year follow-up | 20.2% | 17.0% | 1.28 (0.91–1.80) | P = 0.15 | |
| 0.512Adjusted hazard ratio (log scale) |
- Primary endpoint by baseline LVEF (prognosis): LVEF ≤40%: 213 (17.4%); LVEF >40%: 1010 (82.6%)
Safety
- Safety profile comparable to control across all LVEF categories
- Genitourinary infections more frequent with dapagliflozin
Original publication
Treatment effects of dapagliflozin in patients with aortic stenosis undergoing transcatheter aortic valve implantation across left ventricular ejection fraction. Eur J Heart Fail. Published 27 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →